Corgenix Med Corp (CONX) 0.2640 $CONX
U.S. In-Vitro Diagnostic Substances Market 2015 - Analysis And Forecast to 2020
M2 - Tue Jan 19, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2b394/u_s_invitro) has announced the addition of the "U.S. In-Vitro Diagnostic Substances Market - Analysis And Forecast to 2020" report to their offering. The report provides an in-depth analysis of the U.S. In-Vitro Diagnostic Substances market. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. In addition, the report contains insightful information about the industry, including industry life cycle, business locations, productivity, employment and many other crucial aspects. The Company Profiles section contains relevant data on the major players in the industry. Data coverage: - Market size; - Domestic production, value of shipments; - Key market players and their profiles; - Exports, imports and trade balance; - Import and export prices; - Forecast of the market dynamics in the medium term; - Key industry statistics; - Life cycle of the industry; - Number of establishments and their locations; - Employment data; - Industry productivity. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Domestic Production 5. Imports 6. Exports 7. Competitive Landscape 8. Company Profiles - Abbott Diabetes Care - Orasure Technologies - Amag Pharmaceuticals - Streck - Diasorin Inc. - Diadexus - Rapid Pathogen Screening - Maine Biotechnology Services - Saladax Biomedical - Corgenix Medical Corporation - George King Bio-Medical - Princeton Biomeditech Corp - Banyan Biomarkers - Anatech - Dxna LLC - CD Diagnostics - Akers Biosciences - Helica Biosystems - Green Mountain Antibodies - Biospacific - Innominata - Phase 2 Discovery - Immuno Concepts - Hepatochem - Lifecare Medical International - Horizon Diagnostic - Immucor Gti Diagnostics - Werfen USA - Ivd Intermediate Holdings B Inc. - Opko Diagnostics - Horizon Diagnostic Inc - Immucor Gti Diagnostics - Werfen USA - Ivd Intermediate Holdings B Inc. - Opko Diagnostics For more information visit http://www.researchandmarkets.com/research/n2..._s_invitro
Dengue Virus Pipeline Review, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/43hcsk/dengue_virus) has announced the addition of the "Dengue Virus - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dengue Virus diagnostic tests pipeline products. Key Topics Covered: - Extensive coverage of the Dengue Virus diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Dengue Virus diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage Benefits of this Report: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Dengue Virus diagnostic tests under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline Companies Mentioned: - Acobiom - Ceres Nanosciences, Inc. - Chembio Diagnostic Systems, Inc. - Corgenix Medical Corporation - Epistem Holdings Plc - FK-Biotecnologia SA - GeneFirst Ltd - InBios International, Inc. - Innova Biotechnology Co., Ltd. - InstantLabs Medical Diagnostics Corporation - Institut Pasteur - Malaysian Bio-Diagnostics Research Sdn Bhd - McGill University - Micronics, Inc. (of Sony Group) - Nanyang Technological University - National University of Singapore - Trinity Biotech Plc - Universitas Padjadjaran - University of California, Berkeley - University of Texas Medical Branch at Galveston - Vircell S.L - Whidiag SAS Report Structure: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Products under Development 4 Dengue Virus - Pipeline Products under Development by Companies 5 Dengue Virus Companies and Product Overview 6 Dengue Virus- Recent Developments 7 Appendix For more information visit http://www.researchandmarkets.com/research/43...ngue_virus
TRIB: 10.88 (+0.05)
ORGENTEC and Corgenix Present Abstracts at 2015 AACC Clinical Lab Expo
PR Newswire - Fri Jul 24, 10:30AM CDT
Corgenix Medical Corporation, the U.S. - based operation of ORGENTEC Diagnostika, is presenting several scientific abstracts at the 2015 American Association for Clinical Chemistry (AACC) Clinical Lab Expo in Atlanta. Three abstracts involve the ReEBOV® Ebola rapid diagnostic test (RDT) with a fourth abstract involving the AtherOx(TM) Assay for assessing heart disease risk.
D-dimer Testing Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2022
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cwrx5b/ddimer_testing) has announced the addition of the "D-dimer Testing Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2022" report to their offering. At present, the in vitro diagnostics market is one of the fastest growing markets globally. This remarkable growth can be attributed to the improved health care awareness, preference of the people for preventive health checkups, accessibility to disease specific tests, and shift from manual to semi-automated and automated instruments. Diagnostic laboratories are facing challenges in delivering high-quality, efficient and timely testing solutions due to rising health care awareness and stringent regulations that put pressure on the health care budgets. This has led to growing adoption of automated solutions and new analyzers that deliver high throughput in lesser time and with enhanced efficiency. Point-of care testing has gained momentum in the past few years to meet the demand for quick turnaround time, thus accelerating reliable results. D-dimer assays and POC kits have been developed to confirm the exclusion of deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC). The D-dimer testing market has been extensively analyzed on the basis of testing methods, applications, and geography. Testing methods include point-of-care testing (POC) and laboratory testing. Laboratory testing has been further segmented into coagulation analyzers and clinical chemistry analyzers. Applications comprise deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC). Each of the segments has been analyzed in detail for market trends, number of D-dimer tests, recent developments, outlook, and opportunities. The report provides current and future market size for each segment and sub-segment for the period from 2014 to 2022, in terms of revenue in USD million and number of tests in million, considering 2012 and 2013 as the base years. The compound annual growth rate (%CAGR) for each market segment has been provided for the forecast period from 2014 to 2022 along with the estimations of market size. The report concludes with the company profiles section that includes key information about the major players in the market. Key players profiled in this report include Abbott Laboratories, Alere, Inc., Beckman Coulter, Inc., Bio/Data Corporation, Becton, Dickinson and Company, Corgenix, F. Hoffman-La Roche Ltd., Helena Biosciences, Siemens Healthcare, Sysmex Corporation, Thermo Fisher Scientific, and Trinity Biotech. Each of these players is profiled in the report considering parameters such as company overview, financial overview, business strategies, product portfolio, and recent developments. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 D-dimer Testing Market Overview Chapter 4 Global D-dimer Testing Market Revenue (USD Million) and No. of Tests (Million), by Testing Method, 2012 - 2022 Chapter 5 Global D-dimer Testing Market Revenue (USD Million) and Volume (No. of Tests in Millions), by Application, 2012 - 2022 Chapter 6 Global D-dimer Testing Market Revenue (USD Million) & Volume (No. of Tests in Millions), by Geography, 2012 - 2022 Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - Beckman Coulter, Inc. - Becton, Dickinson and Company - Bio/Data Corporation - Corgenix Medical Corporation - F. Hoffmann-La Roche Ltd. - Helena Biosciences - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc. - Trinity Biotech plc For more information visit http://www.researchandmarkets.com/research/cw...er_testing
ABT: 37.73 (-0.02), TRIB: 10.88 (+0.05), ALR: 42.50 (+0.55)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 171.37 (+0.14), COO: 165.56 (+1.28), SNN: 34.06 (+0.20), VCYT: 5.20 (-0.08), ABAX: 45.98 (+0.62), DYSL: 1.42 (-0.01), VOLC: 17.99 (+0.01), CLLS: 27.69 (-0.09), COHR: 93.50 (-0.24), HRC: 51.12 (+0.05)
Top 100 Global Medical Devices Not Active in India: 2015 Industry Report
M2 - Mon Mar 09, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3gp8dw/global_medical) has announced the addition of the "Global Medical Devices Not Active in India 100: An Industry Report" report to their offering. In India, with a rising population level and higher national growth rates and income levels, the demand for medical devices is expected to grow at a rate of over 15% per year. Though India presents an attractive market opportunity for global medical device manufacturers, the country has never been able to tap into its potential as a domestic manufacturing base. Despite having a medical device market that ranks in the world's top 20, the industry has a long history of being under-resourced. Recently, in a bid to boost investment in the $7 billion medical device sector, the Indian government announced that foreign companies could now fully own existing medical device manufacturers in the country, without the need to get prior approvals. This easing of existing regulations has been done to encourage foreign direct investment since the domestic capital market was not able to provide the much needed investment in this sector. The international companies in this field would now be able to use India as a manufacturing base easily by either setting up facilities of their own or by acquiring domestic manufacturers. FDI inflow will spur R&D and manufacturing innovations, in turn increasing the efficiency and effectiveness of medical electronic products. Advancement of medical electronic product quality and associated successful diagnostic rates are expected to create a spurt in adoption. Report Highlights: - Leading global 100 medical devices companies with no presence in India - Integration of company news and industry news, as well as rankings - Important M&A and alliances among global medical devices companies not active in India - International presence of global medical devices companies not active in India - R&D activities by global medical devices companies not active in India Companies Mentioned - Sample of the Top 100 Companies - A&T Corporation (Japan) - Abaxis Inc(United States) - Abiomed, Inc. (United States) - Advanced Technology Company (Kuwait) - Alphatec Holdings, Inc. (United States) - American Science and Engineering, Inc. (United States) - Atricure, Inc. (United States) - Atrion Corporation (United States) - Austar Lifesciences Ltd (Hong Kong) - Bastide le Confort Medical (France) - Baumer S.A. (Brazil) - Bioquell plc(United Kingdom) - Biosensors International Group Ltd (Singapore) - Canon Electronics Inc.(Japan) - China Medicine Health Industry Co. Ltd(China) - China Renji Medical Group Limited (Hong Kong) - China Resources Wandong Medical Equipment Company Limited (China) - Compumedics Limited (Australia) - Corgenix Medical Corporation(United States) - Create Medic Co., Ltd. (Japan) For more information visit http://www.researchandmarkets.com/research/3g...al_medical
ATEC: 0.25 (unch), ABAX: 45.98 (+0.62), ASEI: 36.88 (+4.54)
Corgenix Signs Memorandum of Understanding Regarding Settlement of Litigation and Announces Plan to Adjourn Special Meeting to December 10
BusinessWire - Wed Nov 19, 4:09PM CST
Corgenix Medical Corporation (OTCQB: CONX.OB) (the "Company"
announced today that it has entered into a memorandum of understanding with plaintiffs' counsel in the consolidated Nevada putative shareholder class action lawsuit described in the Company's definitive proxy statement dated October 21, 2014, as supplemented (the "Proxy Statement" , in connection with the Company's proposed merger with an affiliate of Orgentec Diagnostika (the "Merger" .
Corgenix down to Q1 2014 net loss of USD770,000
M2 - Thu Oct 30, 6:02AM CDT
Diagnostic test company Corgenix Medical (Other OTC:CONX) announced on Wednesday its net loss of USD770,000 for the first quarter ended 30 September 2014.
Corgenix Announces Preliminary Revenue and Net Loss Results for Quarter ended September 30, 2014
BusinessWire - Wed Oct 29, 8:35AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today reported preliminary revenue results for the first quarter (ended September 30, 2014), which came in at approximately $2.2 million versus approximately $2.9 million for the same quarter in the previous year. In addition, due to the lower revenues and the expenses related to the pending strategic merger with Orgentec Diagnostika, the Company incurred a net loss for the period of approximately $770,000 versus net income of approximately $84,000 for the same quarter in the previous year.
U.S. In-Vitro Diagnostic Substances Market 2015 - Analysis And Forecast to 2020
M2 - Tue Jan 19, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2b394/u_s_invitro) has announced the addition of the "U.S. In-Vitro Diagnostic Substances Market - Analysis And Forecast to 2020" report to their offering. The report provides an in-depth analysis of the U.S. In-Vitro Diagnostic Substances market. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. In addition, the report contains insightful information about the industry, including industry life cycle, business locations, productivity, employment and many other crucial aspects. The Company Profiles section contains relevant data on the major players in the industry. Data coverage: - Market size; - Domestic production, value of shipments; - Key market players and their profiles; - Exports, imports and trade balance; - Import and export prices; - Forecast of the market dynamics in the medium term; - Key industry statistics; - Life cycle of the industry; - Number of establishments and their locations; - Employment data; - Industry productivity. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Domestic Production 5. Imports 6. Exports 7. Competitive Landscape 8. Company Profiles - Abbott Diabetes Care - Orasure Technologies - Amag Pharmaceuticals - Streck - Diasorin Inc. - Diadexus - Rapid Pathogen Screening - Maine Biotechnology Services - Saladax Biomedical - Corgenix Medical Corporation - George King Bio-Medical - Princeton Biomeditech Corp - Banyan Biomarkers - Anatech - Dxna LLC - CD Diagnostics - Akers Biosciences - Helica Biosystems - Green Mountain Antibodies - Biospacific - Innominata - Phase 2 Discovery - Immuno Concepts - Hepatochem - Lifecare Medical International - Horizon Diagnostic - Immucor Gti Diagnostics - Werfen USA - Ivd Intermediate Holdings B Inc. - Opko Diagnostics - Horizon Diagnostic Inc - Immucor Gti Diagnostics - Werfen USA - Ivd Intermediate Holdings B Inc. - Opko Diagnostics For more information visit http://www.researchandmarkets.com/research/n2..._s_invitro
Dengue Virus Pipeline Review, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/43hcsk/dengue_virus) has announced the addition of the "Dengue Virus - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dengue Virus diagnostic tests pipeline products. Key Topics Covered: - Extensive coverage of the Dengue Virus diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Dengue Virus diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage Benefits of this Report: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Dengue Virus diagnostic tests under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline Companies Mentioned: - Acobiom - Ceres Nanosciences, Inc. - Chembio Diagnostic Systems, Inc. - Corgenix Medical Corporation - Epistem Holdings Plc - FK-Biotecnologia SA - GeneFirst Ltd - InBios International, Inc. - Innova Biotechnology Co., Ltd. - InstantLabs Medical Diagnostics Corporation - Institut Pasteur - Malaysian Bio-Diagnostics Research Sdn Bhd - McGill University - Micronics, Inc. (of Sony Group) - Nanyang Technological University - National University of Singapore - Trinity Biotech Plc - Universitas Padjadjaran - University of California, Berkeley - University of Texas Medical Branch at Galveston - Vircell S.L - Whidiag SAS Report Structure: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Products under Development 4 Dengue Virus - Pipeline Products under Development by Companies 5 Dengue Virus Companies and Product Overview 6 Dengue Virus- Recent Developments 7 Appendix For more information visit http://www.researchandmarkets.com/research/43...ngue_virus
TRIB: 10.88 (+0.05)
ORGENTEC and Corgenix Present Abstracts at 2015 AACC Clinical Lab Expo
PR Newswire - Fri Jul 24, 10:30AM CDT
Corgenix Medical Corporation, the U.S. - based operation of ORGENTEC Diagnostika, is presenting several scientific abstracts at the 2015 American Association for Clinical Chemistry (AACC) Clinical Lab Expo in Atlanta. Three abstracts involve the ReEBOV® Ebola rapid diagnostic test (RDT) with a fourth abstract involving the AtherOx(TM) Assay for assessing heart disease risk.
D-dimer Testing Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2022
M2 - Mon Jul 20, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cwrx5b/ddimer_testing) has announced the addition of the "D-dimer Testing Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2022" report to their offering. At present, the in vitro diagnostics market is one of the fastest growing markets globally. This remarkable growth can be attributed to the improved health care awareness, preference of the people for preventive health checkups, accessibility to disease specific tests, and shift from manual to semi-automated and automated instruments. Diagnostic laboratories are facing challenges in delivering high-quality, efficient and timely testing solutions due to rising health care awareness and stringent regulations that put pressure on the health care budgets. This has led to growing adoption of automated solutions and new analyzers that deliver high throughput in lesser time and with enhanced efficiency. Point-of care testing has gained momentum in the past few years to meet the demand for quick turnaround time, thus accelerating reliable results. D-dimer assays and POC kits have been developed to confirm the exclusion of deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC). The D-dimer testing market has been extensively analyzed on the basis of testing methods, applications, and geography. Testing methods include point-of-care testing (POC) and laboratory testing. Laboratory testing has been further segmented into coagulation analyzers and clinical chemistry analyzers. Applications comprise deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC). Each of the segments has been analyzed in detail for market trends, number of D-dimer tests, recent developments, outlook, and opportunities. The report provides current and future market size for each segment and sub-segment for the period from 2014 to 2022, in terms of revenue in USD million and number of tests in million, considering 2012 and 2013 as the base years. The compound annual growth rate (%CAGR) for each market segment has been provided for the forecast period from 2014 to 2022 along with the estimations of market size. The report concludes with the company profiles section that includes key information about the major players in the market. Key players profiled in this report include Abbott Laboratories, Alere, Inc., Beckman Coulter, Inc., Bio/Data Corporation, Becton, Dickinson and Company, Corgenix, F. Hoffman-La Roche Ltd., Helena Biosciences, Siemens Healthcare, Sysmex Corporation, Thermo Fisher Scientific, and Trinity Biotech. Each of these players is profiled in the report considering parameters such as company overview, financial overview, business strategies, product portfolio, and recent developments. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 D-dimer Testing Market Overview Chapter 4 Global D-dimer Testing Market Revenue (USD Million) and No. of Tests (Million), by Testing Method, 2012 - 2022 Chapter 5 Global D-dimer Testing Market Revenue (USD Million) and Volume (No. of Tests in Millions), by Application, 2012 - 2022 Chapter 6 Global D-dimer Testing Market Revenue (USD Million) & Volume (No. of Tests in Millions), by Geography, 2012 - 2022 Chapter 7 Recommendations Chapter 8 Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - Beckman Coulter, Inc. - Becton, Dickinson and Company - Bio/Data Corporation - Corgenix Medical Corporation - F. Hoffmann-La Roche Ltd. - Helena Biosciences - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc. - Trinity Biotech plc For more information visit http://www.researchandmarkets.com/research/cw...er_testing
ABT: 37.73 (-0.02), TRIB: 10.88 (+0.05), ALR: 42.50 (+0.55)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 171.37 (+0.14), COO: 165.56 (+1.28), SNN: 34.06 (+0.20), VCYT: 5.20 (-0.08), ABAX: 45.98 (+0.62), DYSL: 1.42 (-0.01), VOLC: 17.99 (+0.01), CLLS: 27.69 (-0.09), COHR: 93.50 (-0.24), HRC: 51.12 (+0.05)
Top 100 Global Medical Devices Not Active in India: 2015 Industry Report
M2 - Mon Mar 09, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3gp8dw/global_medical) has announced the addition of the "Global Medical Devices Not Active in India 100: An Industry Report" report to their offering. In India, with a rising population level and higher national growth rates and income levels, the demand for medical devices is expected to grow at a rate of over 15% per year. Though India presents an attractive market opportunity for global medical device manufacturers, the country has never been able to tap into its potential as a domestic manufacturing base. Despite having a medical device market that ranks in the world's top 20, the industry has a long history of being under-resourced. Recently, in a bid to boost investment in the $7 billion medical device sector, the Indian government announced that foreign companies could now fully own existing medical device manufacturers in the country, without the need to get prior approvals. This easing of existing regulations has been done to encourage foreign direct investment since the domestic capital market was not able to provide the much needed investment in this sector. The international companies in this field would now be able to use India as a manufacturing base easily by either setting up facilities of their own or by acquiring domestic manufacturers. FDI inflow will spur R&D and manufacturing innovations, in turn increasing the efficiency and effectiveness of medical electronic products. Advancement of medical electronic product quality and associated successful diagnostic rates are expected to create a spurt in adoption. Report Highlights: - Leading global 100 medical devices companies with no presence in India - Integration of company news and industry news, as well as rankings - Important M&A and alliances among global medical devices companies not active in India - International presence of global medical devices companies not active in India - R&D activities by global medical devices companies not active in India Companies Mentioned - Sample of the Top 100 Companies - A&T Corporation (Japan) - Abaxis Inc(United States) - Abiomed, Inc. (United States) - Advanced Technology Company (Kuwait) - Alphatec Holdings, Inc. (United States) - American Science and Engineering, Inc. (United States) - Atricure, Inc. (United States) - Atrion Corporation (United States) - Austar Lifesciences Ltd (Hong Kong) - Bastide le Confort Medical (France) - Baumer S.A. (Brazil) - Bioquell plc(United Kingdom) - Biosensors International Group Ltd (Singapore) - Canon Electronics Inc.(Japan) - China Medicine Health Industry Co. Ltd(China) - China Renji Medical Group Limited (Hong Kong) - China Resources Wandong Medical Equipment Company Limited (China) - Compumedics Limited (Australia) - Corgenix Medical Corporation(United States) - Create Medic Co., Ltd. (Japan) For more information visit http://www.researchandmarkets.com/research/3g...al_medical
ATEC: 0.25 (unch), ABAX: 45.98 (+0.62), ASEI: 36.88 (+4.54)
Corgenix Signs Memorandum of Understanding Regarding Settlement of Litigation and Announces Plan to Adjourn Special Meeting to December 10
BusinessWire - Wed Nov 19, 4:09PM CST
Corgenix Medical Corporation (OTCQB: CONX.OB) (the "Company"
announced today that it has entered into a memorandum of understanding with plaintiffs' counsel in the consolidated Nevada putative shareholder class action lawsuit described in the Company's definitive proxy statement dated October 21, 2014, as supplemented (the "Proxy Statement" , in connection with the Company's proposed merger with an affiliate of Orgentec Diagnostika (the "Merger" . Corgenix down to Q1 2014 net loss of USD770,000
M2 - Thu Oct 30, 6:02AM CDT
Diagnostic test company Corgenix Medical (Other OTC:CONX) announced on Wednesday its net loss of USD770,000 for the first quarter ended 30 September 2014.
Corgenix Announces Preliminary Revenue and Net Loss Results for Quarter ended September 30, 2014
BusinessWire - Wed Oct 29, 8:35AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today reported preliminary revenue results for the first quarter (ended September 30, 2014), which came in at approximately $2.2 million versus approximately $2.9 million for the same quarter in the previous year. In addition, due to the lower revenues and the expenses related to the pending strategic merger with Orgentec Diagnostika, the Company incurred a net loss for the period of approximately $770,000 versus net income of approximately $84,000 for the same quarter in the previous year.
